Resistance in Hematologic Malignancies and Cancer

After completing her studies, Dr. Messingerova started working at the Slovak Technical University, Faculty of Chemical and Food Technology, as well as at the Slovak Academy of Sciences in the Centre for Biosciences, where she leads a team dealing with the development of resistance to hypomethylating agents (HMAs) in patients with myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). In her work, she focuses on changes in apoptotic pathways, transport, and metabolism of HMAs in sensitive and resistant AML cell lines. The goal of her team's work is to identify an easily and quickly detectable marker of response to HMA treatment, since it is known that after the failure of this treatment in patients unsuitable for intensive therapy, only the possibility of inclusion in clinical trials or palliative care remains. Albert Breier is Professor at the Faculty of Chemical and Food Technology, Slovak University of Technology, and Chief Research fellow at the Institute of Molecular Physiology and Genetics, Centre of Biosciences, Slovak Academy of Sciences, Bratislava, Slovak Republic, Chief Research Fellow. He holds a PhD in Biochemistry and is the author of more than 130 scientific publications that were more than 1200 times cited. His research interest is anti-cancer agents

• 1. Drug classification for treatment Hematological Malignancies2. Reduce drug uptake in development of resistance3. The Role of Enhanced Drug Efflux in Drug Resistance4. MicroRNAs and other non-coding RNA species in diagnostics, prognostics and therapy response of blood cancers.5. Switching between autophagy and apoptosis pro-survival and pro-death balance in leukemia cells6. The role of UPR signaling pathways in cancer cell resistance to chemotherapy7. Altered cell cycle regulation8. Deregulation of drug metabolizing enzymes and transporters in cancer via the aryl hydrocarbon receptor9. Immune system in resistance prediction10. Mechanisms of resistance of antibody-drug conjugates – obstacles to overcome11. Resistance to Chimeric Antigen Receptor T Cells (CAR-T)